Why Your NPN Application Gets Rejected: Common Deficiencies in Health Canada Submissions

Most NPN applicants expect their first submission to succeed. The sheer volume of licences Health Canada has issued — more than 120,000 Natural Product Numbers since the Natural Health Products Regulations (NHPR, SOR/2003-196) came into force in January 2004 — makes the process feel well-trodden. And it is. But that doesn’t mean it’s forgiving.

A significant proportion of applications come back with a Clarification Request (CR) or a Notice of Deficiency (NOD) before any licence decision is issued. A CR can add 60 or more business days to a Class II review that already carries a 180 business day target. An NOD effectively restarts the clock. For products tied to a launch window or a contracted retail listing, that timeline expansion has real commercial consequences.

Understanding why these deficiencies get issued — and how to prevent them — is among the most cost-effective investments you can make before pressing submit to Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD).

The NHPR’s Evidence Framework (And Where Applicants Fall Into the Gap)

Under Section 5 of the NHPR, every NPN application must demonstrate safety, efficacy, and quality for the product as proposed. Health Canada accepts three categories of evidence, and the category you select has direct consequences for your review class and timeline.

Compendial (monograph-based) evidence draws on the NNHPD’s Compendium of Monographs, which covers more than 400 single-ingredient categories. If your product’s medicinal ingredients, health claims, dose, and dosage form all fall within the relevant monograph parameters, you qualify for a Class I review — targeted at 60 business days.

Well-established use requires peer-reviewed literature demonstrating safe and effective use for at least 25 years in human populations.

Traditional use requires at least 50 years of documented historical use, with the last 25 of those years within a recognized traditional medicine system such as Ayurvedic, Traditional Chinese Medicine, or Indigenous medicinal traditions.

The most common mistake we see in first-time submissions isn’t ignorance of these categories — it’s mixing them without recognizing what that means for application class. An applicant using a compendial ingredient but requesting a health claim not listed in the corresponding monograph isn’t filing a Class I application. They’re filing a Class II. And unless they realize that before Health Canada does, they’re about to receive a Clarification Request pointing it out.

The Five Deficiencies That Delay NPN Applications Most Often

After supporting submissions across a wide range of NHP categories — botanicals, vitamins and minerals, homeopathic medicines, and traditional preparations — these are the patterns that appear repeatedly.

1. Label Claim–Evidence Mismatch

This is the single most common trigger for a Notice of Deficiency. Every proposed label claim must be supported by the exact type of evidence submitted — not a close approximation, not a claim from an adjacent monograph category.

Here’s a typical scenario: an applicant submits traditional use evidence (50-year historical use in Traditional Chinese Medicine) for a claim like “helps maintain joint health.” That exact claim exists in the NNHPD Compendium as a monograph-based claim for glucosamine. Health Canada will flag the mismatch immediately — the claim belongs to the compendial pathway, not the traditional use pathway, and the application class, evidence type, and label claim wording must all be internally consistent. Misalignment on any one element generates a deficiency.

2. Incomplete Ingredient Specifications

Under Schedule 1 of the NHPR, every medicinal ingredient must be described with its proper name, common name, source material, part of the organism used, quantity per dosage unit, and extraction ratio where applicable. Botanical submissions are particularly prone to gaps here.

Listing “ginger root extract” without specifying the plant part, extraction solvent, or standardized constituent (for example, 5% gingerols) will generate a CR almost immediately. Non-medicinal ingredients carry their own requirements — Health Canada maintains a list of acceptable non-medicinal ingredients, and any NMI not on that list, even an otherwise harmless novel coating agent, will flag during the review.

3. Dosage Form and Dose Range Discrepancies

Health Canada publishes a list of accepted dosage forms for natural health products. Submitting a product in a format not on that list — without corresponding safety data supporting the novel delivery format — creates an immediate deficiency. We see this with newer formats: functional gummies, dissolvable oral strips, and single-serve stick packs are commercially popular, but the regulatory framework hasn’t always kept pace with market innovation. Assuming a new format is acceptable without verifying it first is a reliable path to a CR.

Dose range discrepancies are equally problematic. If your proposed label dose differs from the dose range studied in your supporting evidence by more than a modest margin, Health Canada will request safety bridging data demonstrating that the proposed dose is supported. Even a 25% variance from the evidence-based dose range is enough to trigger that request.

4. Attestation Errors and Missing Site Licence Details

Every NPN application must include valid Site Licence numbers for each facility involved in manufacturing, packaging, labelling, and importing the product. Each of those activities requires a separate site licence under Section 14 of the NHPR — and Health Canada cross-checks application data against the site licence registry.

Applicants frequently omit site licence information for secondary manufacturing steps, particularly when contract manufacturers are involved. The attestation confirming GMP compliance must align with current Health Canada GMP guidelines for licensed NHPs. Missing, expired, or incorrectly formatted attestations generate CRs without exception. This is an area where the 2023 update to Health Canada’s Good Manufacturing Practices Guidance for Licensed Natural Health Products added new specificity — particularly around environmental monitoring and batch release documentation. If your site licence pre-dates that update and hasn’t been re-evaluated against the revised guidance, it’s worth addressing before your next application cycle.

5. Insufficient Evidence Quality for Non-Compendial Claims

For Class II applications relying on well-established use evidence, and Class III applications involving novel ingredients or new health claims, Health Canada applies a formal hierarchy of evidence. Randomized controlled trials rank higher than observational studies. Human clinical data ranks above animal models. In vitro data, while scientifically valuable, generally doesn’t satisfy the evidence standard for a physiological health claim on a natural health product label.

A common submission error is building an evidence dossier heavily weighted toward bench science — cell culture studies and animal pharmacology — for a claim that requires human evidence under the NNHPD’s evidence requirements. Health Canada reviewers will not substitute one evidence tier for another. If your dossier leans on preclinical data for a clinical claim, plan for a Notice of Deficiency requesting additional human-study support.

Practical Steps to Reduce Your CR and NOD Risk

A pre-submission review doesn’t need to be elaborate to be effective. These steps address the majority of avoidable deficiencies.

Map every claim to its evidence pathway before anything else. Identify each proposed label claim and determine which evidence category supports it. If one claim is monograph-based and another requires traditional use evidence, you may reduce risk by filing separate single-indication applications rather than a multi-claim application with mixed evidence types. The added filing cost is almost always less than the delay cost of a deficiency notice.

Run each ingredient specification against the Compendium line by line. For every medicinal ingredient, compare your proposed specification against the corresponding monograph — source material, plant part, extraction ratio, dose range, dose frequency, duration of use, and any risk information. Any deviation from monograph parameters means you’re no longer in Class I territory. Know that before Health Canada does.

Verify site licence currency for every facility in your supply chain. Site licences must be valid at the time of application and must remain valid for the duration of the licence term. Contact your contract manufacturer and any third-party labellers or packagers to confirm their current site licence status — and their GMP compliance documentation — before finalizing your submission package.

Review Health Canada’s published CR templates. The NNHPD publishes guidance on common application deficiencies. Going through those templates before submission is the regulatory equivalent of reviewing a marking rubric before an exam. It won’t catch every possible issue, but it will surface the most predictable ones.

Use Health Canada’s pre-submission consultation for complex products. For novel ingredients, unusual dosage forms, or products with ingredients lacking monograph coverage, the NNHPD’s pre-submission meeting program allows applicants to discuss classification, evidence requirements, and label claim acceptability before filing. The consultation adds a few weeks to your pre-submission timeline. It routinely saves months on the back end.

What a Deficiency Actually Costs You

The direct cost of a Clarification Request is measured in time. A single CR on a Class II application — against a 180 business day baseline — can push your total review timeline to 12 to 14 months, and Health Canada’s processing times have historically exceeded their own published targets during high-volume periods.

The indirect costs compound quickly. Reformulating after a Notice of Deficiency often means rebuilding the evidence package. If retail label copy was already developed, it needs revision. If contract manufacturing agreements were priced against a specific launch date, schedule extensions typically carry financial penalties. And if your product was positioned for a seasonal launch window — a vitamin D product timed for the fall, or a sports nutrition NHP for the spring fitness cycle — a six-month delay doesn’t just push the timeline, it erases the opportunity.

The natural health products regulations in Canada aren’t getting simpler. The NNHPD operates under real resource constraints, and there’s no priority queue for incomplete or deficient submissions. Getting your NPN application right the first time isn’t an optimization — it’s the only approach that makes commercial sense.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• Third-Party NHP Potency and Identity Testing for COA Support — Qalitex Laboratories provides ISO 17025-accredited testing to verify ingredient identity and label claims for Canadian NPN submissions.
• EU Natural Health Product Market Entry and Compliance — Care Europe supports natural health brands navigating EU 1223/2009 and REACH requirements for European market expansion.